Stem-cell treatment arrives in Kamloops – Merritt Herald

Photo courtesy of Kamloops This Week.

By: Jessica Wallace (Kamloops This Week)

Gail Walsh didnt want to spend the rest of her days waiting.

The 72-year-old retired Peachland woman said she needed surgical procedures on both knees, hip, neck and back, but didnt want to sit on the waiting list. Instead, she researched alternatives and learned about a doctor in Kelowna offering private stem-cell treatment.

The retired teachers aid committed $6,500 with the hopes of checking some items off her list of procedures.

I thought, I can just see the rest of my days, waiting for surgery after surgery, then recuperating in between, Walsh told KTW. It just seemed to me it was worth the money to try.

Helping people on wait lists is among reasons why a longtime Kamloops neurosurgeon recently began offering stem-cell treatment, despite the fact the procedure is not approved by Health Canada.

The expense [of stem-cell treatment], itll never be offered in the public system, so Canada will be behind the rest of the world, Dr. Richard Brownlee told KTW.Lots of people will do medical tourism, theyll go to Mexico or the States or Germany or whatever to get treatment thats not available here. Wait lists are the other thing.People wait for a year to get a MRI, so if they dont have to wait, they can come in and get one in less than a week or two.

The Welcome Back Centre, a private pain-management clinic on Columbia Street, began offering stem-cell treatment three months ago.

Stem cells are prevalent in humans and can be extracted to help treat degenerative, inflammatory or autoimmune conditions, Brownlee said.

Under the right conditions, stem cells can adapt into other cells. Someone with arthritis may have stem cells injected into a joint to create new cartilage, while athletes may treat soft tissue after a muscle tear, he said.

Brownlee noted the medicine is evolving, even being used to slow down symptoms of but not cure amyotrophic lateral sclerosis (ALS/Lou Gehrigs Disease.)

Stem cells are what do the repairing, Brownlee said. So, if youre putting a big number of those locally at the site of where the injury is, it just encourages healing.

Controversy has surrounded embryonic stem-cell harvest from fetuses. Brownlee said it is both unethical and risky, being that young cells have the potential to change into anything, including cancer.

Much like organ transplant, there is also the risk of the body rejecting them. Brownlees office extracts stem cells from the adults who are receiving them.

If youre taking it directly from the person and processing it and putting it right back in, theres no issues with it, he said.

Brownlee said stem-cell treatment is ideal for people who either havent healed adequately or who have developed degenerative changes over time. Ranging from $5,000 to $10,000 per treatment, it is often sought as a last resort.

The centre has treated about a half-dozen knees and hips and is expanding into other treatments.

Nothing has 100 per cent effectiveness, but most of the conditions, about 85 per cent of people get benefit, Brownlee said.

In offering the first treatment of its kind in the city, Brownlee is educating the public and keeping up with new developments. He just got back from a conference in Beverly Hills through the Cell Surgical Network and said he is looking at joining the group to gain access to data from more than 7,000 cases.

Its just new and different and its something that will probably never be offered through the public system, he said.

As for Walsh, seven weeks after her first treatment, she said its too early to determine if the procedure was successful. Relief could take up to nine months.

All I know is so far, theres nothing harmful done, she said.

Future of stem cells

While Dr. Richard Brownlee said stem-cell treatment will likely never be offered publicly, Prime Minister Justin Trudeau last year announced $20 million in funding to the Centre for Commercialization of Regenerative Medicine to help establish a stem-cell therapy development facility in Toronto.

Regenerative medicine is the future and not only is it the future, its a branch of medicine that Canada and the province of Ontario are actually quite good at, Trudeau was quoted at the time in a story in the Globe and Mail about the announcement.

The medical advances and innovations happening right here in Toronto are world class.

Common applications:

Knees: partial to complete ligament tears, osteoarthritis, partial to complete meniscal tears, augmented ACL or PCL reconstruction;

Shoulder: partial to complete rotator cuff tears, labral tears, osteoarthritis;

Foot and ankle: tendon inflammation, osteoarthritis, patron to complete Achilles tendon tear;

Elbow, wrist and hand: partial to complete ligament tears, epicondylitis, osteoarthritis;

Spine: discogenic back pain, facet arthritis, degenerative disc disease;

Hip: osteoarthritis, labral tears, articular cartilage injuries, avascular necrosis.

Did you know?

Stem cells can be injected locally or delivered intravenously.

Gordie Howe underwent stem-cell therapy after having a stroke and responded well. His family said it helped him walk again, improved his speech and helped him gain weight.

Fat contains 100 to 1,000 times more stem cells than bone marrow.

Excerpt from:
Stem-cell treatment arrives in Kamloops - Merritt Herald

Plastic Surgery Junkie Melanie Tries Stem Cell Treatments In Bid To Turn Back Time – Radar Online

Aging actress Melanie Griffith has turned to unproven and risky science in a desperate bid to turn back the clock!

RadarOnline.com has learned plastic surgery junkie Griffith recently returned to the mysterious ACQUA Klinik in Germany for the second time in six months for stem cell treatments.

The clinic claims the procedure will bring back the fullness and elasticity of your skin, minimize wrinkles and activate hair growth on your head.

PHOTOS: Fab At 58? Melanie Griffiths Lumps & Bumps Exposed In Blue Bikini

Melanie is crazy about the treatment! a source close to the Working Girl star who turns 60 in August revealed. Shes convinced that the clinics special therapy actually turns back time! She believes it replenishes and rejuvenates her skin, using her own cells, so she looks young again!

The clinic offers the Hollywood Aesthetics program developed by Dr. Augustinus Bader, a professor of stem cell technology, whos reportedly developed a miracle cure for aging.

The program is touted as a groundbreaking system that reactivates endogenous stem cells and renews the skin via a miracle hydrogel.

PHOTOS: They Said It! The 24 Most Explosive & Bizarre Celebrity Interviews Ever

Using an ointment instead of a scalpel to turn back the hands of time sounds tempting, especially for Melanie, who has been a victim of botched cosmetic procedures for years, one insider revealed.

The once fresh-faced actress has admitted to having a breast lift and collagen injections.

But Griffith, who has battled drug and booze demons, appears to have done much more, according to experts.

PHOTOS: How Bizarre! 20 Kooky, Crazy Celebrity Conspiracy Theories

I believe shes had both her upper and lower eyelids done, plus a brow lift and chin implant, said plastic surgeon Dr. Brian Glatt, who has not treated the star.

Cosmetic surgeon Dr. Anthony Youn, who has also not worked with Griffith, believes the four-time divorce also had cheek enhancements, as well as plumping thats left her with duck lips.

Griffith has insisted she quit going under the knife years ago, and she has tried to claim she had no clue how drastically cosmetic procedures had changed her face.

PHOTOS: Solanges Erratic Elevator Beat-Down Of Jay Z Isnt The First Time Shes Shocked: A Look Back At Some Of Her Most Bizarre Moments

No, I didnt [realize] until people started saying, Oh, my God! What has she done? I was so hurt, Griffith recalled.

I went to a different doctor, and he started dissolving all of this st that this other woman doctor had put in. Hopefully, I look more normal now.

However, expert Dr. Gabe Mirkin, who hasnt treated the star, warned Melanie could be sorely disappointed: Unchanged stem cells by themselves have not been proven to cure disease or prolong lives.

We pay for juicy info! Do you have a story for RadarOnline.com? Email us at tips@radaronline.com, or call us at (866) ON-RADAR (667-2327) any time, day or night.

Follow this link:
Plastic Surgery Junkie Melanie Tries Stem Cell Treatments In Bid To Turn Back Time - Radar Online

TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa Clinical Study – PR Newswire (press release)

TissueGene has been awarded a $750,000 clinical grant from the Maryland Technology Development Corporation (TEDCO) via the MSCRF. The clinical grant is to be used for conducting clinical trials in Maryland using cell therapy. This money is part of Accelerating Cure, a new TEDCO initiative to support regenerative medicine and cell therapy technologies in Maryland.

The grant award will be used by TissueGene to fund a component of a clinical study at a Maryland location for its US Phase III clinical trial for Invossa. The ultimate outcome of this study is the verification that Invossa exerts its therapeutic effect not only by tissue regeneration but on other inflammatory aspects of the disease such as synovitis.

The title of the grant is "Assessment of the Efficacy of TG-C in Treating Synovitis Using Contrast Enhanced MRI in a Clinical Study of Knee Osteoarthritis." The Principal Investigator (PI) for the study will be Dr. Gurdyal Kalsi, Chief Medical Officer of TissueGene.

"We are excited to support this important clinical trial and the growth of TissueGene in Maryland," said Dr. Dan Gincel, TEDCO's VP University Partnerships, and MSCRF's Executive Director. "We look forward to see many more patients treated and cured from this and other devastating diseases."

Woosok Lee, CEO of TissueGene stated, "As a Maryland-based company, TissueGene is honored by the grant award from the State of Maryland which has consistently demonstrated its commitment to supporting innovative therapies such as Invossa, which could potentially be the world's first disease-modifying drug for treating osteoarthritis."

Invossa is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a single intra-articular injection. Clinical trials completed in Korea and on-going trials in the US have demonstrated pain relief, increased mobility, and improvements in joint structure offering substantial convenience for the nearly 33 million Americans with osteoarthritis who would otherwise be in need of surgery.

TissueGene, Inc. TissueGene, Inc., is a Maryland-based regenerative medicine company specializing in cell and gene therapy. TissueGene's lead product is Invossa, an allogeneic, cell and gene therapy for osteoarthritis of the knee that has completed Phase II clinical trials in the US. TissueGene has recently reached an agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment (SPA) for a Phase 3 clinical trial for Invossa. Information can be found at the NIH registry, ww.clinicaltrials.gov. For additional information about TissueGene, Inc., please visit http://www.tissuegene.com.

The Maryland Stem Cell Research Fund (MSCRF) was established by the State of Maryland under the Maryland Stem Cell Research Act of 2006 to promote State-funded stem cell research and cures through grants and loans to public and private entities in the State. Administered by The Maryland Technology Development Corporation (TEDCO), the MSCRF is overseen by an independent Commission that sets policy and develops criteria, standards and requirements for applications to the Fund. For more information about the Maryland Stem Cell Research Fund, please visit http://www.mscrf.org.

The Maryland Technology Development Corporation (TEDCO) is the go-to source for entrepreneurial support and guidance for technology start-ups and early-stage companies engaged in bringing innovative ideas to market. For over nineteen years, the organization has provided funding, mentoring and networking opportunities to support Maryland's innovation ecosystem. It is frequently ranked as one of the most active seed/early-stage investors in the nation. The organization plays a key role in bringing research created in Maryland's educational institutions and federal laboratories into the commercial marketplace. For more information on TEDCO and its programs and resources, visit http://www.TEDCO.md.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tissuegene-awarded-750000-maryland-stem-cell-grant-for-invossa-clinical-study-300482506.html

SOURCE TissueGene, Inc.

http://www.tissuegene.com

Read this article:
TissueGene Awarded $750000 Maryland Stem Cell Grant for Invossa Clinical Study - PR Newswire (press release)

New Texas Law on Stem Cell Treatments: Showdown With FDA Coming? – Regulatory Focus

Posted 28 June 2017 By Zachary Brennan

With a new Texas law now in the books to allow companies to sell unproven stem cell treatments without US Food and Drug Administration (FDA) approval, some experts wonder when FDA will step in to shut down companies and clinics exposing people to unapproved medical products.

Similar to the Right to Try laws spreading across the US and attempting to undercut FDAs regulation of investigational products, the Texas law, which had been brewing in some form since 2012, applies to certain investigational stem cell treatments for patients with certain severe chronic diseases or terminal illnesses.

And though the Texas law says that it applies to stem cell treatments currently under investigation in clinical trials, it also blocks the Texas Medical Board from revoking, failing to renew or suspending a physicians license based solely on the physicians recommendations to an eligible patient regarding access to or use of an investigational stem cell treatment.

An investigation by Nature in 2012 uncovered unproven and costly stem cell treatments being sold in Texas.

Leigh Turner, anassociate professorat the University of Minnesotas Center for Bioethics and School of Public Health and co-author of a paper in Cell on the selling of stem cell therapies directly to US consumers, explained to Focus the unpredictable nature of Texas law, as the state already has one of the highest concentrations of unregulated stem cell clinics (California and Florida also have high concentrations of such clinics, he said, noting his investigation found more than 500 such clinics in the US).

There are lots of credible stem cell researchers in Texas, but theyre not the ones pushing for this bill, Turner said, noting that the greatest concern should be focused on clinics offering unproven stem cell treatments for a range of diseases with few or no treatment options, like ALS, autism, spinal cord injuries and others.

And though there are provisions in the bill that, according to Turner, could knock some businesses out of the marketplace in Texas, he said its hard to know which way itll break, though it seems clearly based on the fantasy that Texans have to go elsewhere to receive these investigational stem cell therapies.

FDA has so far let these direct-to-consumer stem cell clinics flourish and has only issued a limited number of warning letters to companies like Cell Vitals in 2014, Irvine Stem Cell Treatment Center in 2015 and Lavian in 2016.

Former FDA Commissioner Robert Califf, Center for Biologics Evaluation and Research Director Peter Marks and CBER Deputy Director Celia Witten in December 2016 made the case in the New England Journal of Medicine that the hype over such treatments outpaces the evidence that they are safe and effective, though the agency has not cracked down on the direct-to-consumer stem cell market.

FDA couldve done something since 2009, this is a marketplace thats been around a while, Turner said.

And because many of the clinics engage in interstate commerce, Turner said they do clearly fall within FDAs jurisdiction. But its not just FDA, he added, the Federal Trade Commission could also act, as could state consumer protection agencies or state medical boards.

So why isnt FDA taking action? The agency did not respond to a request for comment and Turner said he has not received a straight answer from the agency.

Will they knock out these businesses? Talking with FDA, I didnt hear that, he said, adding that he did not get the impression that theres a comprehensive, organized plan to deal with the emergence of such a large and growing marketplace.

Read more:
New Texas Law on Stem Cell Treatments: Showdown With FDA Coming? - Regulatory Focus

U team discovers ‘powerhouse’ new treatment in fight against deadly skin disease – Southernminn.com

Jonathan Pitre is a teenager who loves to write science fiction as an escape from the painful disease that causes his body to be coated with wounds.

But the breakthrough bone-marrow transplant he just received at the University of Minnesota is anything but fantasy.

A decade after performing the worlds first bone marrow transplants to treat epidermolysis bullosa a rare and potentially fatal skin disease university researchers believe they have discovered a powerhouse new formula that advances their research, helps the body grow new skin and will allow patients such as Pitre, 17, to live longer, less painful lives.

Its really not miraculous. It certainly isnt science fiction, said Dr. Jakub Tolar, director of the Us stem cell institute and the world leader in transplant therapies for EB. Its based on the hard work of our predecessors. You accomplish something and then you use that knowledge to enhance the next step and the next step.

When they conducted the first transplants using donor bone marrow and umbilical cord blood in 2007, Tolar and colleagues were trying to produce a collagen that binds skin together and is lacking in EB patients. But they had little certainty about the types of cells that would work best.

Since then, research discoveries have allowed them to home in on mesenchymal stem cells, which they believe are uniquely good at bullying their way into the body and producing the missing collagen.

This is the first time ever, that I know of, when you are infusing them with the goal that these cells will stay, Tolar said. They will graft into the skin, set up shop there. Its as if these mesenchymal stem cells are coming home.

The doctors have also focused on transplants involving bone marrow from relatives, which is more familiar to the body and less likely to be rejected by the recipients.

A transplant like Jonathans occurs in a one-two punch. After receiving radiation and chemotherapy treatments to suppress the immune system, the patient receives an infusion of hematopoietic blood stem cells from a donor. Their job in this procedure is to give the patient a new immune system that wont reject the donors mesenchymal cells when they are transplanted later.

Since the U received federal approval last fall to offer the treatment experimentally, seven patients have undergone the procedure.

Tolar said all seven are progressing though Jonathan needed a second transplant this spring because the first one failed to knock out his old immune system.

Jonathan suffered an infection after his most recent transplant, which forced him to return to the hospital this month with high fevers and blisters on his face and mouth. Even so, Jonathans mother, Tina Boileau, said she has been taking pictures since the latest transplant to document the progress for her son, whose back is covered with wounds but for a healthy spot on his right shoulder blade.

Theyre actually in scabs, a sign of healing, said Boileau, who was the bone marrow donor for her sons transplant. Which Ive never seen before.

10 patients died

EB afflicts about one in every 30,000 to 50,000 people, though some forms are more severe than others. While it is known largely for the grotesque skin wounds it causes, the disease is often fatal because it leads to severe infections or skin cancers. It can also create internal wounds to the patients digestive tract, which impairs eating.

The desperation of children with the disorder and their families compelled the first transplants at the university in 2007. Even using the old approach, about two-thirds of patients saw improvements, but 10 of the first 30 recipients died from their diseases or complications of treatment.

The Us latest success with mesenchymal stem cells might end up being an incremental step. Earlier this year, Tolar and his colleagues published research showing success in an even more advanced therapy: laboratory testing using gene editing that can reprogram the patients cells to produce healthy skin cells and tissue.

Further successes could lead to clinical trials in which a patients own dysfunctional cells would be reprogrammed, preventing the need for chemotherapy and the replacement of their immune systems.

Before they came to the U, Boileau said, her son had run out of options. Managing his pain, once possible with over-the-counter Advil, had come to require opioid painkillers such as methadone. That made him groggy and complicated his already awkward life at school back home in Ottawa. Jonathan wasnt even able to eat lunch in the school cafeteria for fear of being accidentally bumped and suffering fresh wounds.

Then the Canadian government approved funding to make him his countrys first recipient of an experimental bone marrow transplant for EB. And his home community rallied to support the family. Among other things, he has visited with pro hockey players from the Ottawa Senators, which also issued a contract adding him to their scout staff.

After seeing the pain her son has endured, Boileau said shell never complain about a blister from new shoes. She marvels at his optimism and his use of science fiction reading and writing to escape.

Inspired by the success of Christopher Paolini, who wrote the acclaimed Eragon science fiction novel as a teen, Jonathan has resolved to write his own science fiction book about a teen who develops the ability to overcome EB. The project resulted in long visits and e-mail exchanges between Tolar and his patient about medicine and physics, because Jonathan wants his story grounded in reality.

Theyre almost soul mates, Boileau said.

Tolar said he enjoys the intellectual relationship and that his patient is providing an example of hope and teaching others about the disease: He may be the only person [who] can bring this kind of view to others, Tolar said.

Read more from the original source:
U team discovers 'powerhouse' new treatment in fight against deadly skin disease - Southernminn.com

A New Path for US Stem Cell Inc (OTCMKTS:USRM) – The Oracle Dispatch

US Stem Cell Inc (OTCMKTS:USRM) is working its way back after a fall last week after news broke the company abandoning RMAT designation for its Myocell product. There was a feeling that the FDA told the company that it was not going to happen and USRM tried to bury the press, but the market saw it and shares tanked.

Since then, shares have been slowly working their way back. The stock is near .06 and has scored a few rips since June 21st, when the price fell to .03. This is an early player in the industry and recently received some nice funding ($5 million from General American Capital Partners).

US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. USRMs discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.

USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases.

According to company materials, US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

You can find outwhen $USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Now that Plan B is in place; however, it is a little unclear of what the ceiling is for USRM. The company will now expand stem cell treatment centers and clinics in the U.S. The company, based in Florida, had recently expanded to Miami Beach, but now the plans call for truly national expansion. USRM will set up stem cell treatment centers in huge metropolitan areas like Dallas, Chicago, Atlanta and Denver. Moreover, the company has emphasized that it will focus squarely on revenue-generating programs that are treating patients right now.

USRMs press detailed the new path for the company: To be clear, U.S. Stem Cell will focus on our revenue generating programs that are treating patients NOWwhich have successfully helped over 7000 patients thus far. Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world. In addition to our efforts at US Stem Cell Training and VetBiologics, our focus will be expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.

US Stem Cell Inc (OTCMKTS:USRM) caught a bad break but still has strong technology and experience to hedge against the tide. USRM is not a company to completely throw out and they carry a market cap of $22.81 million with 335.43 million shares outstanding. We will be providing updates as the company take shape. For continuing coverage on shares of $USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Follow this link:
A New Path for US Stem Cell Inc (OTCMKTS:USRM) - The Oracle Dispatch

Seizures follow similar path regardless of speed, says study – Medical Xpress

June 27, 2017 In this cover drawing for Cell Reports, Columbia researchers illustrate the concept that seizures traveling at different speeds follow the same neuronal firing pattern, just as the above string pattern stays the same whether both hands move closer or farther apart. Credit: Michael Wenzel

Of the 50 million people who suffer from epilepsy worldwide, a third fail to respond to medication. As the search for better drugs continues, researchers are still trying to make sense of how seizures start and spread.

In a new study in Cell Reports, researchers at Columbia University come a step closer by showing that the neurons of mice undergoing seizures fire off in a sequential pattern no matter how quickly the seizure propagatesa finding that confirms seizures are not the result of neurons randomly going haywire.

"This is good news," said the study's senior author, Dr. Rafael Yuste, a neuroscientist at Columbia. "It means that local neuronal circuits matter, and that targeting the right cells may stop or even prevent some types of brain seizure."

To induce the seizures, researchers injected a tiny area of cortex in awake mice with two types of drugsone that increases neuronal firing and another that blocks the inhibitory interneurons that control information flow between cells. Recording the seizures as they rippled outward, researchers found that cells in the mouse's brain systematically fired one after the other. Under both models, the seizure spread across the top layer of cortex in a wave-like pattern before descending into its lower layers.

The video will load shortly

Unexpectedly, they found that whether the seizure lasted 10 seconds or 30 seconds, it followed the same route, like a commuter stuck in traffic. The concept of neurons firing in a reliable pattern no matter how fast the seizure is traveling is illustrated on the cover of Cell Reports, drawn by the study's lead author, Dr. Michael Wenzel.

"The basic pattern of a string stretched between two hands stays the same whether the hands move closer together or farther away," he says. "Just as neurons maintain their relative firing patterns regardless of how slowly or quickly the seizure unfolds."

Researchers were able to get a cell-by-cell view of a seizure propagating through a mouse's brain using high-speed calcium imaging that allowed them to zoom in 100 times closer than electrode techniques used on the human brain.

It may be the first time that researchers have watched a seizure unfold at this level of detail, and their findings suggest that inhibitory neurons may be a promising area of future research, said Dr. Catherine Schevon, a neurology professor at Columbia University Medical Center who was not involved in the research.

"The role of inhibitory restraint in seizure development is an area that few have studied at micrometer scale," she said. "This could be a useful treatment target for future drug development or stem cell interneuron implants."

Explore further: Brain model explores the cause of different epileptic seizure onset patterns

More information: Cell Reports (2017). DOI: 10.1016/j.celrep.2017.05.090

Journal reference: Cell Reports

Provided by: Columbia University

At the onset of an epileptic seizure, differing characteristics of brain tissue surrounding the seizure's origin site may determine which of two main patterns of brain activity will be seen, according to a study in PLOS Computational ...

McLean Hospital and Harvard Stem Cell Institute scientists have new evidence that stem cell transplantation could be a worthwhile strategy to help epileptics who do not respond to anti-seizure drugs.

More than 50 million people of all ages suffer from epilepsy, otherwise known as seizure disorder, the fourth most common neurological disease in the world. Patients diagnosed with epilepsy often experience recurrent seizures ...

More than half of children with epilepsy outgrow their seizures, yet the mechanism underlying this remission is unknown.

Prolonged epileptic seizures may cause serious problems that will continue for the rest of a patient's life. As a result of a seizure, neural connections of the brain may be rewired in an incorrect way. This may result in ...

The ability to reliably pinpoint the anatomical source of epileptic seizures, different for each patient, remains elusive. One third of patients do not respond to medication and an alternative can be surgery to locate and ...

Mice, unlike cats and dogs, are able to move their whiskers to map out their surroundings, much as humans use their fingers to build a 3D picture of a darkened room.

Researchers have identified a network of neurons that plays a vital role in learning vocalizations by aiding communication between motor and auditory regions of the brain.

Behavioral training changes the way attention facilitates information processing in the human brain, a study publishing on June 27 in the open access journal PLOS Biology led by Sirawaj Itthipuripat, at University of California ...

Stroke is an age-related disease that disproportionately affects women. Although experimental studies have identified several hormonal and genetic factors underlying these differences, little is known about how pregnancy ...

While the definitive causes remain unclear, several genetic and environmental factors increase the likelihood of autism spectrum disorder, or ASD, a group of conditions covering a "spectrum" of symptoms, skills and levels ...

Of the 50 million people who suffer from epilepsy worldwide, a third fail to respond to medication. As the search for better drugs continues, researchers are still trying to make sense of how seizures start and spread.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:
Seizures follow similar path regardless of speed, says study - Medical Xpress

Making Babies, No Sex Necessary – The Atlantic

In the future, when a couple wants to reproduce, they will not make a baby in a bed or in the backseat or a car, or under a Keep Off the Grass sign, says Henry Greely, the director of the Center for Law and the Biosciences at Stanford Law School.

Instead, they will go to a clinic. Using stem cells from the couples skin or other non-reproductive organs, scientists will be able to make eggs and sperm, which will be combined into embryos. Each of those embryos will have its own gene sequence, Greely says. The parents will be asked: What do you want to know about these embryos? And theyll be told.

Twenty or 30 years from now, parents will be able to screen their potential kids for genetic abnormalities, pre-disposal to disease, sex, and even cosmetic features like hair, eye, and skin color, Greely claims. The new way of baby-making will save women the pain of going through fertility treatments, he says, and it will prevent disease, save health-care costs, and give non-traditional families more chances to have children. If this reproductive future comes to pass, it will also come with a tangle of moral, legal, and medical questionsones that wont be easy to resolve, despite what Greely may think.

When Greely tells people about his theorywhich is the subject of his 2016 book, The End of Sex and the Future of Human Reproductionthey tend to say, This is Gattica, or this is Brave New World, he said during an interview with the New York Times reporter Carl Zimmer on Monday at the Aspen Ideas Festival, which is co-hosted by the Aspen Institute and The Atlantic. Greely is skeptical of this argument. This is not designer babies. This is not super babies. This is selecting embryos, he said.

Greely gets some of his confidence from the limits of science. Geneticists likely wont be able to predict kids behavioral traits, he said, like their aptitude for math or agility on a sports field. But they may be able to anticipate some traits, like intelligence, in broad strokes. Being able to tell parents that this embryo has a 60 percent chance of being in the top half [of their school class], this embryo has a 13 percent chance of being in the top 10 percentI think thats really possible, he said.

Scientists have been screening embryos using a process called preimplantation genetic diagnosis, or PGD, for two and half decades, Greely said. This allows for the detection of some genetic diseases, as well as determining the sex of the embryo. Up until now, it has been expensive and arduous, but with new technologyincluding the expanded use of stem cellsit will become easy, he said. The people most likely to lead the way on easy PGD are those with fertility trouble, he argues, or those who cant have their own biological kids, including same-sex couples. For these people, the process seems to be a clear potential win: Once hopeless, they may soon be able to have biological children of their own.

But if the process does indeed advance in the way Greely predicts, it will come with big ethical challenges. Safety is a big issue, he said. Coercion is a big issue: Will you be forced to do this? No matter how easy PGD becomes, it will always be expensive, meaning that babies from rich families would gain even more advantages over other people before they leave the womb. The procedure also challenges the disability-rights movement, Greely pointed out: It implicitly suggests that some traits, and thus some people, are preferable to others.

Theres very little about our modern lives that a God from 3000 years ago would have expected.

Some critics may also claim this process is against Gods will, Greely added. I dont have a lot of confidence in the intellectual strength of that argument, but I think it has a lot of visceral support.

Despite Greelys skepticism, this seems to be the greatest potential objection to a world of skin-cell babies and intensive genetic screening: It assumes that the creation of life is a matter of pipettes and petri dishes, not something greater. While the widespread use of contraceptives has largely divorced sex from procreation, this process would represent the final severing. As Greely pointed out, the very meaning of sex would change. Most people have sex and it doesnt result in a baby, he said. They do it because they like it. They do it as a token of love. They do it because theyre forced to. They do it to make money. Pleasure, ultimately, will be a main driver of sex, he added.

For the many peoplereligious or notwho believe that life is not ultimately a matter of science, the world of easy PGD may seem disorienting, even morally disturbing. But Greely didnt think religious or moral arguments could persuade someone like him, or society more broadly, that easy PGD isnt a good idea.

If you, coming from a Catholic background, try to convince me, coming from a non-Catholic background ... that wouldnt work for me, he said. I need a more intellectual argument than one based on my faith or the tablets brought down from the mountain for me say this. Theres very little about our modern lives thats natural or what a God from 3000 years ago would have expected or wanted, including all of modern medicine.

As head-spinning as these theoretical ethical challenges are, perhaps easy PGD wont be as common as Greely thinks. After all, he joked, were never going to get rid of teenagers in the back seat of a car.

Follow this link:
Making Babies, No Sex Necessary - The Atlantic

What makes stem cells into perfect allrounders – Phys.org – Phys.Org

June 27, 2017 Just a few days old embryonic cell clusters: with functional Pramel7 (left), without the protein (right) the development of the stem cells remains stuck and the embyos die. Credit: Paolo Cinelli, USZ

Researchers from the University of Zurich and the University Hospital Zurich have discovered the protein that enables natural embryonic stem cells to form all body cells. In the case of embryonic stem cells maintained in cell cultures, this allrounder potential is limited. Scientists want to use this knowledge to treat large bone fractures with stem cells.

Stem cells are considered biological allrounders because they have the potential to develop into the various body cell types. For the majority of stem cells, however, this designation is too far-reaching. Adult stem cells, for example, can replace cells in their own tissue in case of injury, but a fat stem cell will never generate a nerve or liver cell. Scientists therefore distinguish between multipotent adult stem cells and the actual allrounders - the pluripotent embryonic stem cells.

Epigenetic marks determine potential for development

Differences exist even among the true allrounders, however. Embryonic stem cells that grow in laboratory cell cultures are in a different state than the pluripotent cells found inside the embryos in the first days of development. In a study in the journal Nature Cell Biology, researchers led by Paolo Cinelli of the University Hospital Zurich and Raffaella Santoro of the University of Zurich have now demonstrated the mechanism by which natural allrounders differ from embryonic stem cells in cultures.

At the center of their discovery is a protein called Pramel7 (for "preferentially expressed antigen in melanoma"-like 7) found in the cells of embryonic cell clusters that are just a few days old. This protein guarantees that the genetic material is freed from epigenetic marks consisting of chemical DNA tags in the form of methyl groups. "The more methyl groups are removed, the more open the Book of Life becomes," Cinelli says. Since any cell of the human body can develop from an embryonic stem cell, all genes have to be freely accessible at the beginning. The more a cell develops or differentiates, the stronger its genetic material is methylated and "sealed closed" again. In a bone cell, for example, only those genes are active that the cell requires for its function, the biochemist explains.

Protein is responsible for perfect pluripotency

Despite its short action period of just a few days, Pramel7 seems to play a vital role: When the researchers headed up by Cinelli and Santoro switched off the gene for this protein using genetic tricks, development remained stuck in the embryonic cell cluster stage. In the cultivated stem cells, on the other hand, Pramel7 is rarely found. This circumstance could also explain why the genetic material of these cells contains more methyl groups than that of natural embryonic cells - the perfect allrounders, as Cinelli calls them.

Using the stem cell function to regenerate bone tissue

His interest in stem cells lies in the hope of one day being able to help people with complex bone fractures. "Bones are great at regenerating and they are the only tissue that does not build scars," Paolo Cinelli says. The bone stumps must be touching, however, in order to grow together. When a bone breaks in multiple places and even through the skin, for example, in a motorcycle accident, the sections of bone in between are often no longer usable. For such cases, a bone replacement is required. His team is studying carrier materials that they want to populate with the body's own stem cells in the future. "For this reason, we have to know how stem cells work," Cinelli adds.

Explore further: New tools to study the origin of embryonic stem cells

More information: Urs Graf et al, Pramel7 mediates ground-state pluripotency through proteasomalepigenetic combined pathways, Nature Cell Biology (2017). DOI: 10.1038/ncb3554

Researchers at Karolinska Institutet have identified cell surface markers specific for the very earliest stem cells in the human embryo. These cells are thought to possess great potential for replacing damaged tissue but ...

An International Reserach Team coordinated by Igb-Cnr has discovered a key role of vitamins and amino acids in pluripotent stem cells. The research is published in Stem Cell Reports, and may provide new insights in cancer ...

Scientists have discovered the gene essential for chemically reprogramming human amniotic stem cells into a more versatile state similar to embryonic stem cells, in research led by UCL and Heinrich Heine University.

Pre-eclampsia is a disease that affects 5 to 8 percent of pregnancies in America. Complications from this disease can lead to emergency cesarean sections early in pregnancies to save the lives of the infants and mothers. ...

Oxygen in the air is well known to cause damaging rust on cars through a process known as oxidation. Similarly, a research group at Lund University in Sweden, has now identified that certain cells during embryonic development ...

Human stem cells that are capable of becoming any other kind of cell in the body have previously only been acquired and cultivated with difficulty. Scientists at the Max Delbrck Center for Molecular Medicine (MDC) in the ...

Scientists have developed a new biological tool for examining molecules - the building blocks of life - which they say could provide new insights and other benefits such as reducing the numbers of animals used in experiments.

When insects skip the light fandango their romantic foreplay often involves some pretty crazy things like hypnotic dance moves and flashy colors. In some species it ends with a complex ejaculate package that does more than ...

A study of yeast reveals new mechanism that allows cells to adapt to environmental changes more rapidly by accelerating genetic changes around genes that boost fitness, publishing 27 June in the open access journal PLOS Biology, ...

For us humans, it goes without saying that we reward others as an indication of the gratitude we feel towards them. Scientists from the Max Planck Institutes for Evolutionary Anthropology and for Mathematics in the Sciences ...

Researchers in China have developed a genetic engineering approach capable of delivering many genes at once and used it to make rice endospermseed tissue that provides nutrients to the developing plant embryoproduce ...

In the fight against the viruses that invade everyday life, seeing and understanding the battleground is essential. Scientists at the Morgridge Institute for Research have, for the first time, imaged molecular structures ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more from the original source:
What makes stem cells into perfect allrounders - Phys.org - Phys.Org

Cellect’s Novel Technology Isolates Therapeutic Stem Cells for Regenerative Medicine – Digital Journal (press release)

This press release was orginally distributed by SBWire

New York, NY -- (SBWIRE) -- 06/27/2017 -- Stem cell therapy, a way to replace damaged tissues through regenerative medicine, holds hope for patients everywhere. However, aside from very few applications, cell therapy has not made the leap from laboratory to market. One of the major hurdles have been a cost-effective way of achieving purified stem cells. A big challenge in cell therapy has been separating mature donor cells, which can cause severe damage to the patient, from the donor's stem cells which heal through regenerative medicine. Cellect Biotechnology Ltd., developer of a novel stem cell collection technique, has an effective and elegant technology for harvesting stem cells.

A key component of Cellect's platform technology, ApoGraft, is the ApoTainer which uses cell suicide inducing proteins to kill older cells through apoptosis, or programmed cell death. Cellect has discovered that in an apoptotic environment, mature cells die, while stem cells survive and thrive. The cell selection process is quick, just hours, and the result is a rich, non-toxic batch of stem cells ready to be implanted.

In its first indication, Cellect is evaluating its technology in allogenic (donor) bone marrow transplant (BMT) where up to 50% of patients suffer graft-versus-host disease (GvHD) under current methods, often leading to sickness and death. With the right stem cell procedure, GvHD can be reduced and potentially eliminated.

BMT, a procedure fraught with the chance for GvHD because of its mix of old cells that trigger rejection of tissue implants, is Cellect's initial indication. Cellect demonstrated success in its first stem cell transplant in March using ApoGraft in BMT in its Phase I/II trial, leading to the independent Data and Safety Monitoring Board's (DSMB) approval to continue patient enrollment. A total of 12 patients suffering from blood cancer will be treated, with an eye on efficacy and safety in preventing GvHD.

75,000 BMTs are performed in the US annually at an average cost of $800,000 per transplant, resulting a $60 billion market that is growing due to an aging population and is mainly limited by the GvHD.

Currently, stem cells are either sourced from the patient (autologous) prior to undergoing high-dose chemo or radiation therapy, or they are harvested from donor (allogeneic) stem cells. Chances for perfect donor match for blood cancer patients undergoing BMT are only 25% not good odds. Allogenic donors are subject to an intensive and long procedure including rigorous physical exams, blood samples taken in up to four separate appointments, time commitment of 30 hours spread over four to six weeks, and travel expense.

Both autologous and allogeneic methods can be hazardous because of the combined mix of old cells and vital stem cells that have a better chance to avoid GvHD. This is standard medicine, and not an optimal solution. Cellect's technology eliminate the non-matched immune response carrying cells . Time and money can be saved.

Operating under a well-thought out business model, Cellect plans to out-license its ApoGraft platform to pharma, biotech, research centers and hospitals, furnishing them with an unprecedented tool. Non-exclusive licensing gives Cellect a broad array of potential partners.

Cellect's robust intellectual property protection includes patents that cover all aspects of selecting only the cells needed for the transplantation, with the promise of avoiding GvHD. Yet Cellect's platform is not only for blood cancers. Other future applications can be directed to autoimmune disease such as Juvenile diabetes, all significant markets.

Cellect has drawn leaders in key areas important to further regenerative medicine into mainstream treatment options. Scientific and medical advisors include researchers and practitioners from Dana Farber, Harvard, King's College London, Pfizer Inc., the FDA, and Stanford. All have a deep interest in making stem cell therapy a reality. All will be critical to advising the company on current and future regulatory pathways. All strongly believe in Cellect's technology.

At the end of the first quarter of 2017, Cellect had cash of approximately $7 million. With the stock trading at about $8.50, the market cap is $45 million.

If the Phase I/II study proves successful, Cellect will be well positioned to partner with pharma and biotech firms who will use the ApoGraft platform in whichever applications they wish, giving Cellect an opportunity for ongoing revenue from licensing and royalties. This could boost its cash levels, stock price and market cap.

Cellect leads the world in providing a pioneering method to harvest stem cells that seek to cure many diseases, starting with proof in BMT, without adverse side effects. Its goal is to make ApoGraft available for clinics to use easily and effectively, much like any modern-day medical tool. Its technology is both simple and revolutionary, making stem cell medicine a nearer-term reality than ever before.

RAY DIRKS Research suggests that Readers/Investors place no more than 1% of the funds they devote to common stocks in any one issue. It's best to diversify.

About Ray Dirks Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high -net worth investors both in the U.S. and internationally.

In 1973 Ray uncovered the biggest Ponzi scheme of the 20th century, the Equity Funding fraud. Over the years Ray has expanded his stock market research to include Healthcare Stocks and Special Situations. Ray has written two books, "The Great Wall Street Scandal" and "Heads You Win, Tails You Win," published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals, and he manages money for some individual investors.

For more information, log on to http://www.raydirks.com.

For more information on this press release visit: http://www.sbwire.com/press-releases/cellects-novel-technology-isolates-therapeutic-stem-cells-for-regenerative-medicine-825784.htm

See more here:
Cellect's Novel Technology Isolates Therapeutic Stem Cells for Regenerative Medicine - Digital Journal (press release)